Use access key #2 to skip to page content.

IBDvalueinvestin (99.66)

Something big must have happened at MYRX conference call

Recs

1

September 14, 2009 – Comments (0)

Myriad Pharmaceuticals Announces Two Abstracts Selected for Presentation At 2009
ICAAC Annual Meeting

SALT LAKE CITY, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc.
(Nasdaq:MYRX) today announced that two abstracts have been selected for
presentation at the Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) Annual Meeting, being held September 12-15, 2009, in San
Francisco, CA.. Presentations will disclose new findings about MPC-4326, a
Myriad Pharmaceuticals' drug candidate being developed as an oral treatment of
human immunodeficiency virus 1 (HIV-1) infection.

The abstracts can be accessed through the ICAAC website http://www.icaac.org/.
Abstract titles are provided below, however, please note that according to ICAAC
policy, all data are embargoed until the presentation time. Once presented, all
posters and presentations will be available as PDF files on the Myriad
Pharmaceuticals' website (http://www.myriadpharma.com/).

Abstract # H1230 (Monday, Sep. 14, 2009, 10:00 AM - 10:15 AM): Efficacy, Safety
and Pharmacokinetics of MPC-4326 (Bevirimat Dimeglumine) 200mg bid and 300mg bid
Monotherapy Administered for 14 days in Subjects with HIV-1 Infection

Abstract # A1-1309 (Monday, Sep. 14, 2009, 11:15 AM - 1:15 PM): Pharmacokinetics
and Safety of a Novel 100 mg Tablet Formulation of MPC-4326 in Subjects with
HIV-1 Infection

About MPC-4326

MPC-4326 (bevirimat dimeglumine) is MPI's investigational new drug being
developed as an oral treatment of human immunodeficiency virus 1 (HIV-1)
infection. MPC-4326 is a potent small-molecule that acts as a viral maturation
inhibitor and is a first-in-class drug candidate with a novel mechanism of
action. New drugs with novel mechanisms of action are needed to combat the
evolution of HIV drug resistance to the currently available therapies.
Importantly, preclinical studies have demonstrated that MPC-4326 exhibits potent
activity against a broad range of HIV strains, including isolates that are
resistant to currently approved HIV therapies. MPC-4326 could therefore
strengthen the portfolio of approved drugs being used in combination to treat
patients with HIV.

Clinical studies in over 675 subjects to date have shown MPC-4326 to be well
tolerated and have demonstrated significant and clinically relevant reductions
in viral load in patients. Approximately 60% of all HIV patients are infected
with strains of HIV that are sensitive to MPC-4326, and these patients can be
readily detected with a simple and proprietary genotyping assay. MPC-4326 has
been granted Fast Track designation by the U.S. Food and Drug Administration.
The company expects to initiate a 24-week, controlled, two-arm efficacy study
(Phase 2b) of MPC-4326 in HIV treatment-experienced patients in the second half
of 2009.

About Myriad Pharmaceuticals, Inc.

Myriad Pharmaceuticals, Inc. is a biopharmaceutical company focused on
discovering, developing, and commercializing novel small molecule drugs that
address severe medical conditions, including cancer and HIV infection. Our
pipeline includes clinical and pre-clinical product candidates with distinct
mechanisms of action and novel chemical structures that have the potential to be
first-in-class and/or best-in-class therapeutics. For more information visit
www.myriadpharma.com.

The Myriad Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6327

0 Comments – Post Your Own

Featured Broker Partners


Advertisement